<DOC>
	<DOC>NCT02387996</DOC>
	<brief_summary>The purpose the study is to measure the effect of nivolumab (BMS-936558) in reducing tumor size in subjects with metastatic or unresectable bladder cancer.</brief_summary>
	<brief_title>A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Evidence of metastatic or surgically unresectable transitional cell carcinoma of the urothelium involving the bladder,urethra,ureter or renal pelvis Measurable disease by CT or MRI Progression or recurrence after treatment i) With at least 1 platinumcontaining chemotherapy regimen for metastatic or surgically unresectable locally advanced urothelial cancer, or ii) Within 12 months of perioperative (neoadjuvant or adjuvant) treatment with a platinum agent in the setting of cystectomy for localized muscleinvasive urothelial cancer Subject that have received more than 2 prior lines of chemotherapy must not have liver metastases Tumor tissues (archived or new biopsy) must be provided for biomarker analysis Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 Subjects with active cancer that has spread to the central nervous system Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured Subject with active, known or suspected autoimmune disease Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 day of study drug administration Prior treatment with an antiPD1,antiPDL1,antiPDL2,anticytotoxic Tlymphocyteassociated protein 4 (CTLA4) antibody, antiCD137 or any other antibody or drug specifically targeting Tcell costimulation or immune checkpoint pathways Exclusion laboratory criteria: Positive test for hepatitis B virus surface antigen (HBV s Ag) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection Known history of testing positive for human Immunodeficiency virus (HIV) or known acquired Immunodeficiency syndrome (AIDS)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>